This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: October 12, 2009
Last updated: January 21, 2010
Last verified: January 2010
This study is designed to evaluate the safety, tolerability and pharmacokinetics (PK) of two doses of AZD1446 or placebo in subjects when given for 4 weeks.

Condition Intervention Phase
Healthy Drug: AZD1446 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Healthy Elderly Male and Female Volunteers During 4 Weeks of Treatment

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To assess the safety and tolerability of AZD1446 dosed for 4 weeks as compared to placebo in healthy elderly male and female volunteers. Safety and tolerability outcomes include adverse events, clinical chemistry and vitals (pulse and blood pressure). [ Time Frame: During the whole study period, Study days 1-68 (30 days of enrolment , study day 1-28 and follow up visit study days 35-38). ]

Secondary Outcome Measures:
  • To determine the PK of AZD1446 dosed for 4 weeks in healthy elderly male and female volunteers. PK parameters include renal clearance, AUC (0-24)ss and T1/2 eff. [ Time Frame: PK sampling taken at defined timepoints during the treatment period (study days 1-28) ]

Enrollment: 97
Study Start Date: October 2009
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AZD1446 Low
Low dose of AZD1446
Drug: AZD1446
Solution, oral, for 4 weeks
Experimental: AZD1446 High
High dose of AZD1446
Drug: AZD1446
Solution, oral, for 4 weeks
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   65 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or non-fertile female, elderly Subjects, aged ≥65 to ≤85
  • Body mass index (BMI) between 18 and 30 kg/m2
  • Clinically normal findings on physical examination

Exclusion Criteria:

  • History of any clinically significant disease or disorder
  • History of severe allergy/hypersensitivity reactions including severe food allergy as judged by the investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00997308

Lund, Sweden
Sponsors and Collaborators
Principal Investigator: Bo Fransson, MD, PhD AstraZeneca R&DClinical Pharmacology Unit CPUTunavägen 22aS-221 87 LundSweden
Study Director: Björn Paulsson, MD, PhD AstraZeneca R&D SödertäljeSE-151 85 SödertäljeSweden
  More Information

Responsible Party: MSD, AstraZeneca Identifier: NCT00997308     History of Changes
Other Study ID Numbers: D1950C00009
EudraCT No.2009-013390-18
Study First Received: October 12, 2009
Last Updated: January 21, 2010

Keywords provided by AstraZeneca:
to investigate safety and tolerability in Healthy subjects during 4 weeks of administration processed this record on September 20, 2017